Prosecution Insights
Last updated: April 19, 2026
Application No. 18/254,711

FAT ENCAPSULATED MICROBIAL CULTURES

Final Rejection §103
Filed
May 26, 2023
Examiner
TURNER, FELICIA C
Art Unit
1793
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Chr Hansen A/S
OA Round
2 (Final)
26%
Grant Probability
At Risk
3-4
OA Rounds
4y 6m
To Grant
57%
With Interview

Examiner Intelligence

Grants only 26% of cases
26%
Career Allow Rate
162 granted / 626 resolved
-39.1% vs TC avg
Strong +31% interview lift
Without
With
+30.8%
Interview Lift
resolved cases with interview
Typical timeline
4y 6m
Avg Prosecution
62 currently pending
Career history
688
Total Applications
across all art units

Statute-Specific Performance

§101
0.8%
-39.2% vs TC avg
§103
59.5%
+19.5% vs TC avg
§102
9.9%
-30.1% vs TC avg
§112
24.3%
-15.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 626 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . The office action is written in response to the Applicants Remarks filed 1/16/26. Claims 1-8, 10-12, 14, 16-18 are pending and have been examined on the merits. Claims 9, 13, and 15 have been cancelled. Claims 16-18 are new. Withdrawn Rejections The 102(a)(1) rejections of claims 1-9, and 12-14 as being anticipated by Mattson (CA 2636181) have been withdrawn due to the amendments to the claims. The 103(a) rejection of claim 11 over Mattson (CA 2636181) in further view of Koss et al. (US 2003/0147995) has been withdrawn due to the amendment to claim 1. The 103(a) rejection of claim 15 over Mattson (CA 2636181) in further view of Koss et al. (US 2003/0147995) and Kondou (EP 0301502) due to the amendment to claim 1. Claim Rejections - 35 USC § 103 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claims 1-8, 12, 14, and 16-18 are rejected under 35 U.S.C. 103 as being unpatentable over Mattson (CA 2636181) in view of Wang (WO 2016/161506). Regarding Claims 1, 2, 6: Mattson discloses encapsulated probiotics, coated in a fat based composition [abstract]. Mattson discloses a microbial culture preparation [0011; 0013-0016]. Mattson discloses a fat based coating that is substantially solid at room temperature and having a melting point of 90 to about 98°F (32-36°C) [0017; 0019; 0021]. Mattson discloses that the fat coated culture is stable, meaning less than 10% loss for at least 3 months at refrigerated temperatures more preferably about 33 to about 50°F [0038]. Mattson does not disclose that the composition is a post-pasteurized. Mattson does not disclose wherein the microbial culture is viable during post-pasteurization and subsequent storage at a temperature of 25°C for a period of at least 2 weeks. Wang discloses heat treating encapsulated probiotics [abstract; 0001; 0004]. Wang discloses that the encapsulation protects the probiotics from subsequent heat damage [0038; 0039]. Wang discloses the encapsulation material as containing fat with a melting point between 25°C and 60°C [0041; 0043]. Wang discloses carrying out a spray drying treatment at 60 to 85°C [0047; 0048]. The temperatures in Wang are compatible with pasteurization temperatures. At the effective filing date of the invention it would have been obvious to one of ordinary skill in the art to include the encapsulated probiotics of Mattson with a subsequent heat treatment step as in Wang since Wang discloses that the protective effect of fat based coating protects otherwise heat sensitive bacteria from the stress of heat. Since the probiotics of Wang are able to withstand heat treatment steps it would have been obvious that they would have been able to survive other heat processing steps [0048]. Although Mattson as modified by Wang does not disclose wherein the microbial culture is viable during post-pasteurization and subsequent storage at a temperature of 25°C for a period of at least 2 weeks, “Products of identical chemical composition cannot have mutually exclusive properties.” A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present. In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). Since Mattson discloses the same combination of probiotic and fat as recited, it would have been expected to have the same effect or results in post pasteurized yogurt and therefore the same stability at 25°C for at least two weeks. Regarding Claim 3: Mattson discloses as discussed above in claim 1. Mattson further discloses that the one or more fats is cocoa butter, palm oil, palm kernel oil, coconut oil, or shea nut butter [0019; 0021]. Regarding Claim 4: Mattson discloses as discussed above in claim 1. Mattson discloses that the fat can further contain an emulsifier [0023]. Regarding Claim 5: Mattson discloses as discussed above in claim 1. Mattson discloses that the probiotics are in dry viable form and that the fat encapsulating the probiotic is solid at room temperature which is therefore considered a dry form of the product [0013; 0014; 0019]. Regarding Claim 7: Mattson discloses as discussed above in claim 6. Mattson discloses that the probiotics can be Lactobacilli species or Bifidobacteria species [0013]. Regarding Claim 8: Mattson discloses as discussed above in claim 1. Mattson discloses that the microbial culture is lactic acid bacteria [0013]. Regarding Claim 12: Mattson discloses a method of making encapsulated probiotics, by mixing the probiotics with a fat based coating [abstract; 0033]. Mattson discloses a microbial culture preparation [0011; 0013-0016]. Mattson discloses a fat based coating that is substantially solid at room temperature and has a melting point of 90 to about 98°F (32-36°C) [0017; 0019; 0021]. Mattson does not disclose post-pasteurization. Mattson does not disclose wherein the microbial culture is viable during post-pasteurization and subsequent storage at a temperature of 25°C for a period of at least 2 weeks. Wang discloses a method of making encapsulated probiotics [abstract; 0001; 0004]. Wang discloses that the encapsulation protects the probiotics from subsequent heat damage [0038; 0039]. Wang discloses the encapsulation material as containing fat with a melting point between 25°C and 60°C [0041; 0043]. Wang discloses forming the encapsulated probiotics and subsequently carrying out a spray drying treatment at 60 to 85°C [0047; 0048]. The temperatures in Wang are compatible with pasteurization temperatures. At the effective filing date of the invention it would have been obvious to one of ordinary skill in the art to include the encapsulated probiotics of Mattson with a subsequent heat treatment step as in Wang since Wang discloses that the protective effect of fat based coating protects otherwise heat sensitive bacteria from the stress of heat. Since the probiotics of Wang are able to withstand heat treatment steps it would have been obvious that they would have been able to survive other heat processing steps [0048] including pasteurization, especially where the temperatures to which the encapsulated probiotic are exposed are within the range known for pasteurization. Although Mattson as modified by Wang does not disclose wherein the microbial culture is viable during post-pasteurization and subsequent storage at a temperature of 25°C for a period of at least 2 weeks, “Products of identical chemical composition cannot have mutually exclusive properties.” A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present. In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). Since Mattson discloses the same combination of probiotic and fat as recited, it would have been expected to have the same effect or results in post pasteurized yogurt and therefore the same stability at 25°C for at least two weeks. Regarding Claim 14: Mattson as modified discloses as discussed above in claim 1. Mattson discloses food comprising fat encapsulated microbial culture as discussed in claim 1 [0033; 0034; 0042]. Regarding Claims 16-18: Mattison as modified discloses as discussed above in claim 1. Although Mattson as modified by Wang does not disclose wherein the microbial culture is viable during post-pasteurization and subsequent storage at a temperature of 25°C for a period of at least 4 weeks, at least 6 weeks, at least 8 weeks, “Products of identical chemical composition cannot have mutually exclusive properties.” A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present. In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). Since Mattson discloses the same combination of probiotic and fat as recited, it would have been expected to have the same effect or results in post pasteurized yogurt and therefore the same stability at 25°C for at least 4 weeks, for at least 6 weeks, for at least 8 weeks. Claims 10 and 11 are rejected under 35 U.S.C. 103 as being unpatentable over Mattson (CA 2636181) in view of Wang (WO 2016/161506) and Riis et al. (US 2019/0142022). Regarding Claims 10 and 11: Mattison as modified by Wang discloses as discussed in claim 1. Mattson discloses a chocolate coating containing yogurt powder and butter oil and is therefore considered a dairy product since it contains yogurt powder and butter oil and yogurt powder contains milk and butter oil is derived from milk [0042]. Mattson discloses a white coating containing yogurt powder and whole milk powder and is therefore considered a dairy product since yogurt powder contains milk and due to the whole milk powder [0043]. Mattson does not disclose that the composition is a post-pasteurized. Mattson does not disclose wherein the microbial culture is viable during post-pasteurization and subsequent storage at a temperature of 25°C for a period of at least 2 weeks. Wang discloses heat treating encapsulated probiotics [abstract; 0001; 0004]. Wang discloses that the encapsulation protects the probiotics from subsequent heat damage [0038; 0039]. Wang discloses the encapsulation material as containing fat with a melting point between 25°C and 60°C [0041; 0043]. Wang discloses carrying out a spray drying treatment at 60 to 85°C [0047; 0048]. The temperatures in Wang are compatible with pasteurization temperatures. Riis discloses a dairy product which is a post pasteurized yogurt [0178; 0210]. At the effective filing date of the invention it would have been obvious to one of ordinary skill in the art to include the encapsulated probiotics of Mattson with post-pasteurized yogurt as Riis in order to provide ambient temperature yogurt with live bacteria. Although Mattson does not disclose wherein the microbial culture is viable during post-pasteurization and subsequent storage at a temperature of 25°C for a period of at least 2 weeks, “Products of identical chemical composition cannot have mutually exclusive properties.” A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present. In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). Since Mattson discloses the same combination of probiotic and fat as recited, it would have been expected to have the same effect or results in post pasteurized yogurt and therefore the same stability at 25°C for at least two weeks. Response to Arguments The 102(a)(1) rejections of claims 1-9, and 12-14 as being anticipated by Mattson (CA 2636181) have been withdrawn due to the amendments to the claims. The 103(a) rejection of claim 11 over Mattson (CA 2636181) in further view of Koss et al. (US 2003/0147995) has been withdrawn due to the amendment to claim 1. The 103(a) rejection of claim 15 over Mattson (CA 2636181) in further view of Koss et al. (US 2003/0147995) and Kondou (EP 0301502) due to the amendment to claim 1. Pertinent Prior Art The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Adel (CA 2820178) Adel discloses a composition comprising probiotic bacteria, the composition comprising: (a) a core composition containing the probiotic bacteria and a stabilizer, wherein the total amount of probiotics in the mixture is from about 10% to about 90% by weight of the core composition; (b) an innermost coating layer, layered on said core composition, comprising at least one hydrophobic solid fat or fatty acid having a melting point lower than 60 °C; (c) an intermediate coating layer layered on said innermost coating layer, which when present in an aqueous solution in the amount of 0.1% weight/weight over the weight of the solution, has a surface tension lower than 60 mN/m, when measured at 25°C; and (d) an outer coating layer, layered on said intermediate coating layer; wherein the composition is in the form of particles; food products containing the composition and methods of preparation thereof. Swan (US 2009/0074932) Swan discloses post pasteurization [0037; 0039; 0052]. Swan discloses adding live probiotics pre-or post-pasteurization [0060; 0075]. Vurma et al. TW 201336418 discloses that probiotics can be treated by encapsulation of heat resistant probiotics to protect against heat treatment conditions [pg. 17 “Manufacturing”]. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to FELICIA C TURNER whose telephone number is (571)270-3733. The examiner can normally be reached Mon-Thu 8:00-4:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Emily Le can be reached at 571-272-0903. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Felicia C Turner/Primary Examiner, Art Unit 1793
Read full office action

Prosecution Timeline

May 26, 2023
Application Filed
Jul 12, 2025
Non-Final Rejection — §103
Jan 16, 2026
Response Filed
Mar 29, 2026
Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599150
HIGHLY EMULSIFIABLE ALBUMEN HYDROLYSATE
2y 5m to grant Granted Apr 14, 2026
Patent 12543753
Cultured Dairy Products and Method of Preparation
2y 5m to grant Granted Feb 10, 2026
Patent 12538935
PROCESS FOR PRODUCING PURIFIED PAC'S AND SUGAR FROM FRUIT JUICE, AND COMPOSITIONS COMPRISING SAME
2y 5m to grant Granted Feb 03, 2026
Patent 12501922
Canola Based Tofu Product and Method
2y 5m to grant Granted Dec 23, 2025
Patent 12490750
PROCESS FOR DRY AGING MEAT
2y 5m to grant Granted Dec 09, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
26%
Grant Probability
57%
With Interview (+30.8%)
4y 6m
Median Time to Grant
Moderate
PTA Risk
Based on 626 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month